Unique ID issued by UMIN | UMIN000037451 |
---|---|
Receipt number | R000042646 |
Scientific Title | Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events |
Date of disclosure of the study information | 2019/07/29 |
Last modified on | 2022/02/04 14:52:54 |
Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events
Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events
Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events
Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events
Japan |
Lung Cancer
Hematology and clinical oncology |
Malignancy
NO
To examine the association between values of BIA, clinical backgrounds, efficiencies of treatment, and adverse events in lung cancer patients before treatment.
*Values of BIA are Body Mass Index (BMI), Soft Lean Mass(SLM), Fat Free Mass Index(FFMI), Skeletal Muscle Mass Index(SMI), phase angle(Ph A), ratio of extracellular water to total body water(ECW/TBW), ratio of extracellular water to intracellular water(ECW/ICW).
**Clinical backgrounds are age, sex, Performance Status(PS), smoking history, histologic feature, clinical stage, sites of metastases and previous systemic therapies.
Safety,Efficacy
Association between ECW/TBW in BIA and efficiencies or adverse events of anti-cancer treatment
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1.Patient who received ICI plus chemotherapyor platinum doublet alone as first-line regimen
2. Patient with recurrence lung cancer or unresectable progression caner
3.Diagnosis of small cell lung cancer or the non-small-cell lung cancer
4.Patient was 20 years oldor morehe at registration
5. Patient with Performance Status 0-2
5. Patient with the evaluable lesion
6. Written informed consent was obtained from the patient
Patient with a pacemaker
55
1st name | Tomonori |
Middle name | |
Last name | Hirashima |
Osaka Prefectual Hospital Organization
Osaka Habikino Medical Center
Thoracic Oncology
583-8588
3-7-1,Habikino,Habikino-City,Osaka
0729572121
hirashimat@ra.opho.jp
1st name | Tomonori |
Middle name | |
Last name | Hirashima |
Osaka Prefectual Hospital Organization, Osaka Habikino Medical Center
Thoracic Oncology
583-8588
3-7-1,Habikino,Habikino-City,Osaka
0729572121
hirashimat@ra.opho.jp
Osaka Prefectual Hospital Organization
Osaka Habikino Medical Center
Osaka Prefectual Hospital Organization
Osaka Habikino Medical Center
Other
National Hospital Organization Kinki-Chuo Chest Medical Center
Osaka Prefectual Hospital Organization, Osaka Habikino Medical Center
3-7-1,Habikino,Habikino-City,Osaka
0729572121
nishibayashih@opho.jp
NO
地方独立行政法人大阪府立病院機構大阪はびきの医療センター(大阪府)、独立行政法人国立病院機構 近畿中央呼吸器センター(大阪府)
2019 | Year | 07 | Month | 29 | Day |
Unpublished
No longer recruiting
2019 | Year | 04 | Month | 15 | Day |
2019 | Year | 05 | Month | 31 | Day |
2019 | Year | 07 | Month | 29 | Day |
2022 | Year | 05 | Month | 31 | Day |
nothing
2019 | Year | 07 | Month | 22 | Day |
2022 | Year | 02 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042646
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |